Taken together, these findings suggest that DPP1 is an attractive therapeutic target for a number of NSP-mediated pathologies, and DPP1 inhibition is a promising avenue for the treatment of diseases in which neutrophilic inflammation is central to the pathology, such as chronic inflammatory diseases, autoimmune diseases, and cancer. Here, CTSC is linked to autoimmune disease.